

# 10<sup>th</sup> INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

VIENNA, 17-19 NOVEMBER, 2010

M.C. Escher "The Knot"



[www.ifmad.org](http://www.ifmad.org)



Final Programme



## SCIENTIFIC COMMITTEE

### Chairman

Siegfried Kasper (*Austria*)

### Co-Chairman

Stuart A. Montgomery (*United Kingdom*)

### Scientific Advisers

C. Allgulander (*Sweden*), C.A. Altamura (*Italy*), C. Arango (*Spain*),  
D. Baldwin (*United Kingdom*), M. Bauer (*Germany*), P. Boyer (*Canada*),  
G. Burrows (*Australia*), G.B. Cassano (*Italy*), K. Demyttenaere (*Belgium*),  
J. Den Boer (*The Netherlands*), T. Dinan (*Ireland*), E. Eriksson (*Sweden*),  
N. Fineberg (*United Kingdom*), T. Higuchi (*Japan*), S.H. Kennedy (*Canada*),  
J.P. Lépine (*France*), M. Maj (*Italy*), A.A. Mathé (*Sweden*),  
J. Mendlewicz (*Belgium*), H.J. Möller (*Germany*), S. Pallanti (*Italy*),  
G. Papadimitriou (*Greece*), G. Papakostas (*USA*), Z. Rihmer (*Hungary*),  
A.F. Schatzberg (*USA*), D.J. Stein (*South Africa*), T. Suppes (*USA*), E. Vieta (*Spain*),  
L. Von Knorring (*Sweden*), D. Winkler (*Austria*),  
S. Yamawaki (*Japan*), J. Zohar (*Israel*)

## IMPORTANT ADDRESSES

### Organizing Secretariat



Publi Créations

74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

E-mail: [ifmad@publiccreations.com](mailto:ifmad@publiccreations.com) - Website: [www.ifmad.org](http://www.ifmad.org)

### Forum Venue



#### Hotel HILTON

Am Stadtpark 1, Vienna,  
Austria A - 1030

Tel: 43-1-717000

## CONTENTS



Scientific Committee - Important Addresses **2**

Congress Venue **4**

Welcome Letter - Acknowledgement **5**

Programme Overview **6**

Scientific Programme **7**

Posters **12**

Scientific Information **17**

General Information **17**


Announcement of Next Forum **19**

**Web site:**


**[www.ifmad.org](http://www.ifmad.org)** 



# CONGRESS VENUE



Hotel HILTON Am Stadtpark 1, Vienna



## WELCOME LETTER



*It is our pleasure to welcome you in Vienna to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD).*

*IFMAD has become an important Forum for the exchange of ideas on the latest developments in psychiatric treatments where international experts can address in an informal atmosphere some of the important topics in the field of mood and anxiety disorders. The meetings are particularly valued for the high quality of the scientific contributions and the opportunity for focused discussion of new data presented in a constructive and productive environment.*

*Attendees at previous meetings have appreciated the very efficient and agreeable formula provided by IFMAD meetings for keeping up to date with current treatment issues. We look forward to renewing old acquaintances at the next meeting, which will be held in Budapest (9-11 November 2011) and to welcoming an even wider and international audience.*

*We are pleased to welcome you in Vienna and have you with us again this year.*

Siegfried Kasper,  
Chairman

Stuart A. Montgomery,  
Co-Chairman

## ACKNOWLEDGEMENT

*The Organising Committee express their gratitude  
to the following Companies*

**ASTRAZENECA**  
**LUNDBECK A/S**  
**PIERRE FABRE MEDICAMENTS**  
**PFIZER LIMITED**

*for their contribution as Sponsor of Symposia*

**WISEPRESS LTD**  
*for their participation in the exhibition*



## PROGRAMME OVERVIEW

Wednesday, November 17	Thursday, November 18	Friday, November 19
	<b>09.00/10.30</b> Examining opportunities for increasing treatment success in depression and anxiety disorders	<b>09.00/10.30</b> Controversies in resistant depression
	<b>10.30/11.00</b> <i>Coffee break</i>	<b>10.30/11.00</b> <i>Coffee break</i>
	<b>11.00/12.30</b> Treatment of Depression with Comorbidity	<b>11.00/12.30</b> First line treatments post Cipriani
	<b>12.30/13.30</b> <i>Lunch</i>	<b>12.30/13.30</b> <i>Lunch</i>
	<b>13.30/15.00</b> Is bipolar depression different from unipolar depression?	<b>13.30/14.30</b> Augmentation in major depressive disorder - Reviewing the role for atypical antipsychotics
<b>14.30/16.00</b> How can we overcome the stigma against treatment	<b>15.00/16.00</b> Debate: Do the suicide restrictions on antidepressants do more harm than good?	<b>14.30/16.00</b> Treatment mechanism in OCD
<b>16.00/16.30</b> <i>Coffee break</i>	<b>16.00/16.30</b> <i>Coffee break</i>	<b>16.00/16.15</b> <i>End of meeting</i>
<b>16.30/18.00</b> GAD as an obstacle to successful management of other psychiatric conditions	<b>16.30/18.00</b> The noradrenergic symptom cluster in depression	
<b>18.00/19.00</b> <i>Opening Ceremony</i>		

NB: This agenda is subject to change





**WEDNESDAY, 17 November 2010**

**14.30 - 16.00 SO 01 - HOW CAN WE OVERCOME THE STIGMA AGAINST TREATMENT**

Chair: ***Elias Eriksson (Sweden),  
Carlo A. Altamura (Italy)***

SO 0101 How can we neutralise the stigma of the treatment of depression

***Jiri Raboch (Czech Republic)***

SO 0102 The need for early onset treatments in depression and anxiety

***Carlo A. Altamura (Italy)***

SO 0103 Stigma against PMDD caused by regulatory action

***Elias Eriksson (Sweden)***

**16.00 - 16.30 Coffee break**

**16.30 - 18.00 SO 02 - GAD AS AN OBSTACLE TO SUCCESSFUL MANAGEMENT OF OTHER PSYCHIATRIC CONDITIONS**

Chair: ***Siegfried Kasper (Austria)***

SO 0201 Preclinical work in anxiety: Latest insights

***Johan A. Den Boer (The Netherlands)***

SO 0202 Concurrent anxiety: Increasing the burden of other psychiatric disorders

***Hans-Jürgen Möller (Germany)***

SO 0203 Optimizing treatment in the presence of anxiety

***Siegfried Kasper (Austria)***

***Symposium sponsored by an unrestricted educational grant from Pfizer Limited***

**18.00 - 19.00 Opening Ceremony**



## SCIENTIFIC PROGRAMME

**THURSDAY, 18 November 2010**

**09.00 - 10.30 SO 03 - EXAMINING OPPORTUNITIES  
FOR INCREASING TREATMENT SUCCESS  
IN DEPRESSION AND ANXIETY DISORDERS**

Chair: ***Siegfried Kasper (Austria)***

SO 0301 Therapeutic drug monitoring of antidepressants: controversies and possibilities

***Gerald Zernig (Austria)***

SO 0302 Prioritising safety and efficacy in the treatment of elderly patients

***Eva Topinková (Czech Republic)***

SO 0303 Is the choice of antidepressant a major factor in attaining the treatment goal?

***Stuart Montgomery (UK)***

SO 0304 Treatment myths - a panel discussion

***Siegfried Kasper (Austria)***

***Symposium sponsored by an unrestricted  
educational grant from H. Lundbeck A/S***

**10.30 - 11.00 Coffee break**

**11.00 - 12.30 SO 04 - TREATMENT OF DEPRESSION  
WITH COMORBIDITY**

Chair: ***Cristina Sampaio (Portugal)***

***Jean-Pierre Lépine (France)***

SO 0401 Treatment of Parkinsons disease and depression

***Cristina Sampaio (Portugal)***

SO 0402 Influence of comorbid anxiety disorders on outcome in major depression

***David Baldwin (UK)***

SO 0403 Pharmacotherapy of neuropsychiatric manifestations of HIV/AIDS

***Christer Allgulander (Sweden)***

**12.30 - 13.30 Lunch**





## 13.30 - 15.00 **SO 05 - IS BIPOLAR DEPRESSION DIFFERENT FROM UNIPOLAR DEPRESSION?**

Chair: **David Baldwin (UK), Eduard Vieta (Spain)**

- SO 0501 Symptom profile and outcome in bipolar and unipolar depression  
**Jules Angst (Switzerland)**
- SO 0502 A review of the evidence for monotherapy in bipolar depression  
**Eduard Vieta (Spain)**
- SO 0503 Augmentation strategies for bipolar and unipolar depression  
**Michael Bauer (Germany)**

## 15.00 - 16.00 **SO 06 - DEBATE: DO THE SUICIDE RESTRICTIONS ON ANTIDEPRESSANTS DO MORE HARM THAN GOOD?**

Chair: **Stuart Montgomery (UK)**

Pro: **Zoltan Rihmer (Hungary)**

Contra: **Karl Broich (Germany)**

## 16.00 - 16.30 **Coffee break**

## 16.30 - 18.00 **SO 07 - THE NORADRENERGIC SYMPTOM CLUSTER IN DEPRESSION**

Chair: **Stuart Montgomery (UK)**

- SO 0701 Introduction: What is the noradrenergic symptom cluster?  
**Stuart Montgomery (UK)**
- SO 0702 The increasing burden of depressive disorder  
**Jean-Pierre Lépine (France)**
- SO 0703 The noradrenergic symptom cluster - clinical expression and neuropharmacology  
**Pierre Blier (Canada)**
- SO 0704 Improvement of the noradrenergic symptom cluster following treatment with milnacipran  
**Siegfried Kasper (Austria)**

**Symposium sponsored by an unrestricted educational grant from Pierre Fabre Medicaments**



## SCIENTIFIC PROGRAMME

**FRIDAY, 19 November 2010**

### **09.00 - 10.30 SO 08 - CONTROVERSIES IN RESISTANT DEPRESSION**

Chair: ***Daniel Souery (Belgium)***  
***Alessandro Serretti (Italy)***

- SO 0801 Resistant depression state or trait:  
genetic and clinical evidence?  
***Alessandro Serretti (Italy)***
- SO 0802 Do current guidelines interfere with identifying and treating  
resistant depression  
***Stuart Montgomery (UK)***
- SO 0803 Advances in the treatment of resistant depression  
***Daniel Souery (Belgium)***

**10.30 - 11.00** **Coffee break**

### **11.00 - 12.30 SO 09 - FIRST LINE TREATMENTS POST CIPRIANI**

Chair: ***Hans Jürgen Möller (Germany)***  
***Naomi Fineberg (UK)***

- SO 0901 Multiple treatments meta-analysis of antidepressants for  
major depression: strengths and weaknesses?  
***Andrea Cipriani (Italy)***
- SO 0902 Mixed-treatments comparison meta-analysis of  
antidepressants: implications for everyday clinical practice  
***Corrado Barbui (Italy)***
- SO 0903 Are direct double-blind comparisons the best tests  
of superiority?  
***Hans-Jürgen Möller (Germany)***

**12.30 - 13.30** **Lunch**



### **13.30 - 14.30 SO 10 - AUGMENTATION IN MAJOR DEPRESSIVE DISORDER – REVIEWING THE ROLE FOR ATYPICAL ANTIPSYCHOTICS**

Chair: **Stuart Montgomery (UK)**

SO 1001 When treatment fails - a review of the evidence for atypical antipsychotics as an augmentation strategy in MDD

**Michael Bauer (Germany)**

SO 1002 Symptom control - an important outcome for depressed patients

**Borwin Bandelow (Germany)**

***Symposium sponsored by an unrestricted educational grant from AstraZeneca***

### **14.30 - 16.00 SO 11 - TREATMENT MECHANISMS IN OCD**

Chair: **Michael Bauer (Germany)**  
**Naomi Fineberg (UK)**

SO 1101 Augmentation strategies in resistant OCD

**Stefano Pallanti (Italy)**

SO 1102 Relevance of cognitive dimensions in the treatment of OCD

**Naomi Fineberg (UK)**

SO 1103 Do imaging studies improve treatment strategies in OCD?

**Martijn Figee (The Netherlands)**

### **16.00 - 16.15 *End of meeting***



**P 01.** The effects of typical and atypical anti-psychotics on inducing obsessive-compulsive symptoms in patients with schizophrenia

**A. Afkham Ebrahimi**

*Iran University of Medical Sciences, Tehran, Iran*

**P 02.** Some therapeutic approaches to anxiety disorders in late life

**M. Arnaoudova-Jekova**

*Medical University, Varna, Bulgaria*

**P 03.** The many faces of anxiety in later life

**M. Arnaoudova-Jekova**

*Medical University, Varna, Bulgaria*

**P 04.** Effects of cholinergic system of medial prefrontal cortex on anxiety-related behaviors

**A. Bakhtiari, J. Solati, A.A. Salari**

*Department of Biology, Faculty of Science, Islamic Azad University, Karaj Branch, Karaj, Iran*

**P 05.** A double-blind, placebo-controlled study of augmentation with LY2216684 for major depressive disorder patients who are partial responders to selective serotonin reuptake inhibitors

**S. Ball, M. Dellva, D. D'Souza, L. Marangell, J. Russell, C. Goldberger**

*Eli Lilly and Company, Indianapolis, USA*

**P 06.** Pooled analysis of the efficacy of adjunctive *quetiapine* XR in patients with major depressive disorder and high or low levels of baseline anxiety

**B. Bandelow<sup>1</sup>, M. Bauer<sup>2</sup>, E. Vieta<sup>3</sup>, N. El-Khalili<sup>4</sup>, M. Udd<sup>5</sup>, U. Gustafsson<sup>5</sup>, H. Eriksson<sup>5</sup>**

*<sup>1</sup>University of Goettingen, Department of Psychiatry and Psychotherapy, Goettingen, Germany,*

*<sup>2</sup>University Hospital Carl Gustav Carus, Department of Psychiatry and Psychotherapy, Dresden, Germany, <sup>3</sup>University of Barcelona, Bipolar Disorders Program, Hospital Clinic, IDIBAPS, CIBER-SAM, Barcelona, Spain, <sup>4</sup>Alpine Clinic, Department of Psychiatry, Lafayette, USA, <sup>5</sup>AstraZeneca, R&D, Södertälje, Sweden*

**P 07.** Predictive factors of remission for treatment-resistant major depressive disorder (MDD) during treatment with extended-release *quetiapine* fumarate (*quetiapine* XR)

**M. Bauer<sup>1</sup>, S. Kasper<sup>2</sup>, L. Dell'Ossso<sup>3</sup>, W. Pichot<sup>4</sup>, B.T. Baune<sup>5</sup>, J. Köhler<sup>6</sup>, L. Jørgensen<sup>7</sup>, E. Dencker-Vansvik<sup>7</sup>, S. Montgomery<sup>8</sup>**

*<sup>1</sup>University Hospital Carl Gustav Carus, Technische Universität Dresden, Department of Psychiatry and Psychotherapy, Dresden, Germany, <sup>2</sup>Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria, <sup>3</sup>University of Pisa, Department of Psychiatry, Pharmacology, Neurobiology and Biotechnology, Pisa, Italy, <sup>4</sup>University of Liège, Psychiatric Unit, Liège, Belgium, <sup>5</sup>James Cook University, Psychiatry & Psychiatric Neuroscience, Queensland, Australia, <sup>6</sup>AstraZeneca, Medical Department, Wedel, Germany, <sup>7</sup>AstraZeneca, Department of Medical Affairs, Södertälje, Sweden, <sup>8</sup>Imperial College, London, UK*

**P 08.** Adjunctive *quetiapine* XR and its effects on sleep disturbance and quality: a pooled analysis from two acute studies in MDD

**M. Bauer<sup>1</sup>, R.S. McIntyre<sup>2</sup>, J. Szamosi<sup>3</sup>, H. Eriksson<sup>3</sup>**

*<sup>1</sup>University Hospital Carl Gustav Carus, Department of Psychiatry and Psychotherapy, Dresden, Germany, <sup>2</sup>University Health Network, University of Toronto, Department of Psychiatry, Toronto, Canada, <sup>3</sup>AstraZeneca, R&D, Södertälje, Sweden*

**P 09.** Long-term adjunctive *aripiprazole* therapy for treatment-resistant bipolar disorder

**K. Bongjin**

*Department of Psychiatry, Seoul National University, Bundang Hospital, Seoul, South Korea*



**P 10.** Improvement of sexual function in depressed outpatients treated with milnacipran  
**M. Briley<sup>1</sup>, R. Moreno<sup>2</sup>**

<sup>1</sup>NeuroBiz Consulting & Communication, Castres, France, <sup>2</sup>Mood Disorders Unit - Department of Psychiatry, University of São Paulo Medical School, Sao Paulo, Brazil.

**P 11.** Is poor Insight Obsessive-Compulsive Disorder a distinct subtype?  
**A. V. Cherian, R. Srinivasaraju, J.C. Narayanaswamy, B. Viswanath, S. Bada Math, Y.C. Janardhan Reddy**

National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.

**P 12.** Plasma serotonin level of vietnam war veterans with posttraumatic stress disorder and symptom severity

**M. Chung<sup>1</sup>, S. Kang<sup>2</sup>, T. Lee<sup>1</sup>, M. Lee<sup>1</sup>**

<sup>1</sup>Seoul Veterans Hospital, Seoul, South Korea, <sup>2</sup>Choonchun National Mental Hospital, Choonchun, South Korea

**P 13.** Demographic, clinical and treatment-related resistance features of Treatment Resistant Depression subjects: preliminary results

**L. Cosentino, N. Bartolomei, F. Luchini, B. Berti, F. Casamassima, L. Palagini, L. Lattanzi, M. Mauri**

Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Pisa, Italy

**P 14.** Antipsychotics in treatment-resistant obsessive-compulsive disorder - a systematic review

**M. Dold, R. Lanzenberger, M. Aigner**

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

**P 15.** The Role of the 5-HT<sub>2C</sub> Receptor Sub-type in preclinical models of Obsessive-Compulsive Disorder

**N. Fineberg, A. Brown**

National Specialist Service for Obsessive Compulsive Disorders, Hertfordshire Partnership NHS Foundation Trust, Queen Elizabeth II Hospital, Welwyn Garden City, UK

**P 16.** Treating depression in parkinson's disease with electroconvulsive therapy

**E. Guertzenstein, J.C.M. Nóbrega, M.J. Teixeira**

Division of Neurosurgery, Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

**P 17.** Identifying CYP2D6 intermediate and poor metabolizers among schizophrenic patients with respect to therapeutical response

**J. Jurica<sup>1</sup>, R. Bartecek<sup>2</sup>, O. Zendulka<sup>1</sup>, T. Kasperek<sup>2</sup>, E. Flodrova<sup>3</sup>, A. Sulcova<sup>1</sup>**

<sup>1</sup>Department of Pharmacology, Faculty of Medicine, Masaryk University, <sup>2</sup>Department of Psychiatry of Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, <sup>3</sup>Department of Medical genetics, Faculty Hospital Brno, Czech Republic

**P 18.** How well do randomized controlled trial data generalize to real world clinical practice settings? Comparison of two generalized anxiety disorder (GAD) studies

**S. Kasper<sup>1</sup>, M. Brasser<sup>2</sup>, E. Schweizer<sup>3</sup>, S. Donevan<sup>4</sup>, G. Lyndon<sup>5</sup>, R. Prieto<sup>6</sup>**

<sup>1</sup>Medical University of Vienna, Vienna, Austria, <sup>2</sup>Pfizer Pharma GmbH, Berlin, Germany, <sup>3</sup>Paladin Consulting Group, Hoboken, NJ, USA, <sup>4</sup>Pfizer Inc., New York, NY, USA, <sup>5</sup>Pfizer Ltd., Tadworth, Surrey, UK, <sup>6</sup>Pfizer España, Madrid, Spain



**P 19.** Is silexan an anxiolytic drug?

**S. Kasper<sup>1</sup>, S. Klement<sup>2</sup>**

<sup>1</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, <sup>2</sup>Schwabe Company, Germany

**P 20.** The efficacy of agomelatine in previously treated depressed patients

**S. Kasper<sup>1</sup>, G. Hajak<sup>2</sup>**

<sup>1</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, <sup>2</sup>Department of Psychiatry, Psychosomatics and Psychotherapy, University of Regensburg, Germany

**P 21.** Prevalence and symptom characteristics of depression in schizophrenia patients

**D. Lee<sup>1</sup>, D.U. Bek<sup>2</sup>**

<sup>1</sup>Bongseng Memorial Hospital, Busan, South Korea, <sup>2</sup>Dongrae Bongseng Hospital, Busan, South Korea

**P 22.** Trauma induced major depression: associated disability

**M. Livingston<sup>1</sup>, A.J. Showman<sup>1</sup>, H.M. Livingston<sup>2</sup>**

<sup>1</sup>Southern General Hospital and University of Glasgow, Glasgow, UK, <sup>2</sup>Royal Alexandra Hospital, Paisley, UK

**P 23.** Brain Neuropeptide Y (NPY) is a marker of PTSD in an animal model

**AA. Mathé<sup>1</sup>, H. Cohen<sup>2</sup>, T. Liu<sup>1</sup>, M.A. Matar<sup>2</sup>, J. Zohar<sup>3</sup>**

<sup>1</sup>Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, <sup>2</sup>Mental Health Center, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel, <sup>3</sup>The Chaim Sheba Medical Center, Sackler Medical School, Tel-Aviv University, Israel

**P 24.** Comorbid mood and anxiety disorders in adult adhd patients

**D. Meshkat, A. Kutzelnigg, C. Eckert, A. Konstantinidis, S. Kasper**

Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria

**P 25.** Anxiety and depression symptoms in children-commorbidity with learning disabilities

**A. Michopoulou, M. Mavilidi, D. Thomas, K. Karmiri, A. Patrou, A. Koutsoukou-Argyraki**

Pentelis Children Hospital, Athens, Greece

**P 26.** Efficacy of pregabalin in elderly patients with generalized anxiety disorder (GAD) who present with high levels of insomnia

**S. Montgomery<sup>1</sup>, Y. Xu<sup>2</sup>, E. Schweizer<sup>3</sup>, S. Donevan<sup>2</sup>, G. Lyndon<sup>4</sup>, R. Prieto<sup>5</sup>**

<sup>1</sup>Imperial College School of Medicine, University of London, London, UK, <sup>2</sup>Pfizer Inc., New York, NY, USA, <sup>3</sup>Paladin Consulting Group, Hoboken, NJ, USA, <sup>4</sup>Pfizer Ltd., Tadworth, Surrey, UK, <sup>5</sup>Pfizer España, Madrid, Spain

**P 27.** Personality and antidepressant adherence: a pilot study

**S. Monzon<sup>1</sup>, M. Gili<sup>1,2</sup>, M.J. Serrano<sup>1,2</sup>, N. Bauza<sup>1,2</sup>, M. Vives<sup>1,2</sup>, M. Garcia-Toro<sup>1,2</sup>, J. Salva<sup>1,2</sup>, C. Mateu<sup>2,3</sup>, C. Vicens<sup>2,3</sup>, F. Bestard<sup>2,4</sup>, T. Ballester<sup>2,5</sup>, M. Roca<sup>1,2</sup>**

<sup>1</sup>Institut Universitari d'Investigació en Ciències de la Salut (Iunics), University of Balearic Islands., Palma, Spain, <sup>2</sup>Red de Investigación en Actividades Preventivas y Promoción de la Salud (Rediapp), Madrid, Spain, <sup>3</sup>Centro de Salud Son Serra-la viletta. IB-Salut, Palma, Spain, <sup>4</sup>Centro de Salud Son Gotleu. IB-Salut, Palma, Spain, <sup>5</sup>Centro de Salud Escola Graduada. IB-Salut, Palma, Spain

**P 28.** Are there phenotypic differences in adults with early and late onset OCD?

**J. C. Narayanaswamy, B. Viswanath, A. V. Cherian, S. Bada Math, Y. C. Janardhan Reddy**

National Institute of Mental health And Neurosciences (NIMHANS), Bangalore, India

**P 29.** Plasma biomarkers to diagnose major depressive disorder

**Y. Ohashi<sup>1</sup>, K. Shinoda<sup>1</sup>, H. Sato<sup>1</sup>, T. Ishikawa<sup>1</sup>, N. Kawamura<sup>2</sup>**

<sup>1</sup>Human Metabolome Technologies, Inc., Tsuruoka, Japan, <sup>2</sup>National Center of Neurology and Psychiatry, Tokyo, Japan



**P 30.** Designing a comparative study of escitalopram versus risperidone for the treatment of behavioral and psychological symptoms in Alzheimer's disease

**D. Paleacu, I. Plopsy, S. Tadger, Y. Barak**

*Abarbanel Mental Health Center associated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*

**P 31.** Prescription of antipsychotics in inpatients with mdd 2000 and 2007 - results from the AMSP International Pharmacovigilance Project

**K. Papageorgiou<sup>1</sup>, A. Konstantinidis<sup>1</sup>, R. Grohmann<sup>2</sup>, A. Horvath<sup>3</sup>, R. Engel<sup>2</sup>, S. Kasper<sup>1</sup>**

*<sup>1</sup>Department of Biological Psychiatry, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Department of Psychiatry, Ludwig Maximilians University, Munich, Germany, <sup>3</sup>Psychiatric Private Clinic Sanatorium Kilchberg/Zurich, Zurich, Switzerland*

**P 32.** The reliability and validity of WHOQOL in patients with breast cancer: physical domain and depression

**S.I. Han, Y.W. Jeon, E.J. Park**

*Department of Psychiatry, Incheon St. Mary's Hospital, The Catholic Universe of Korea*

**P 33.** Public attitudes towards depression and psychiatric medication:barriers to treatment  
**L.E. Peppou, I. Karayanni, G. Skalkotos, D. Kolostoumpis, A. Komporozos, M. Economou**

*University Mental Health Research Institute (UMHRI) -Anti-Stigma Programme, Athens, Greece*

**P 34.** Early vs. delayed switch to duloxetine in patients with major depressive disorder not exhibiting early improvement with escitalopram: a double-blind randomized study

**I. Romera<sup>1</sup>, V. Perez<sup>2</sup>, J.M. Menchon<sup>3</sup>, A. Schacht<sup>4</sup>, R. Papen<sup>5</sup>, D. Neuhauser<sup>6</sup>, I. Gilaberte<sup>1</sup>**

*<sup>1</sup>Eli Lilly and Company, Medical Department, Madrid, Spain, <sup>2</sup>Hospital de Sant Pau i de la Santa Creu, Barcelona, Spain, <sup>3</sup>Hospital Universitari de Bellvitge. Hospitalet de Llobregat, Barcelona, Spain, <sup>4</sup>Eli Lilly and Company, Global Statistical Sciences, Bad Homburg, Germany, <sup>5</sup>Eli Lilly and Company, Bad Homburg, Germany, <sup>6</sup>Eli Lilly and Company, Vienna, Austria*

**P 35.** Efficacy and safety of zolpidem tartrate sublingual tablet for as-needed treatment of middle-of-the-night (MOTN) insomnia

**T. Roth<sup>1</sup>, N. N. Singh<sup>2</sup>, F. Steinberg<sup>3</sup>, A. Krystal<sup>4</sup>**

*<sup>1</sup>Henry Ford Hospital, Detroit, MI, <sup>2</sup>Transcept Pharmaceuticals, Inc, Pt Richmond, CA, <sup>3</sup>Chief Medical Consultant to Transcept Pharmaceuticals, Inc., Evanston, IL, <sup>4</sup>Duke University, Durham, NC, USA*

**P 36.** Treatment of middle of the night insomnia: current therapeutic approaches

**T. Roth<sup>1</sup>, N. N. Singh<sup>2</sup>, D. Cooke<sup>2</sup>**

*<sup>1</sup>Henry Ford Hospital, Detroit, MI, <sup>2</sup>Transcept Pharmaceuticals, Inc., Pt Richmond, CA, USA*

**P 37.** Intra-peritoneal injection of salmonella typhimurium LPS affect anxiety behaviors and serum corticosterone level in pregnant mice and its male offspring

**A.A. Salari<sup>1</sup>, J. Solati<sup>2</sup>, B. Tabaraie<sup>3</sup>, B. Rashidieh<sup>1</sup>, M. Enayati<sup>1</sup>**

*<sup>1</sup>Department of Biology, Young Researchers Club, Islamic Azad University, Karaj Branch,, Karaj, Iran, <sup>2</sup>Department of Biology, Faculty of Science, Islamic Azad University, Karaj Branch, Karaj, Iran, <sup>3</sup>Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran*

**P 38.** Multitracer pet imaging of the serotonergic system

**M. Savli<sup>1</sup>, A. Bauer<sup>2</sup>, D. Häusler<sup>3</sup>, T. Kroll<sup>2</sup>, A. Hahn<sup>1</sup>, F. Rattay<sup>4</sup>, M. Mitterhauser<sup>3</sup>, W. Wadsak<sup>3</sup>, S. Kasper<sup>1</sup>, R. Lanzenberger<sup>1</sup>**

*<sup>1</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Institute of Neuroscience and Medicine (INM-2), Research Centre Jülich, Vienna, Austria, <sup>3</sup>Department of Nuclear Medicine, Medical University of Vienna, Vienna, Austria, <sup>4</sup>Institute for Analysis and Scientific Computing, Vienna University of Technology, Vienna, Austria*





**P 39.** 3D brain SPECT imaging as an aid in the management of resistant depression

**H. Schneider<sup>1</sup>, J. Thornton<sup>2</sup>, R. Tarzwell<sup>3</sup>, M. Freeman<sup>4</sup>, M. Mclean<sup>5</sup>, M. Van Lierop<sup>6</sup>**

<sup>1</sup>Sheppard Clinic, Toronto, <sup>2</sup>Rossiter-Thornton Associates, Toronto, <sup>3</sup>University of British Columbia, Vancouver, <sup>4</sup>University of Toronto, Toronto, <sup>5</sup>Dr. M. McLean, MD, Toronto, <sup>6</sup>Dr. M. van Lierop, MD, Toronto, Canada

**P 40.** Genome wide association scan of co-morbid anxiety in MDD.

**A. Schosser<sup>1,3</sup>, M.Y. Ng<sup>1</sup>, A.W. Butler<sup>1</sup>, R. Uher<sup>1</sup>, S. Cohen-Woods<sup>1</sup>, N. Craddock<sup>2</sup>, M. Owen<sup>2</sup>, K.J. Aitchison<sup>1</sup>, G. Breen<sup>1</sup>, I. Craig<sup>1</sup>, A.E. Farmer<sup>1</sup>, C.M. Lewis<sup>1</sup>, P. McGuffin<sup>1</sup>**

<sup>1</sup>MRC SGDP Centre, Institute of Psychiatry, King's College London, UK, <sup>2</sup>MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, Cardiff University, UK, <sup>3</sup>Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria

**P 41.** Ruptured aneurysm involving right basal ganglia with manic and psychotic features.

**S. Thanasan**

Department of Psychological Medicine, University Malaya, Kuala Lumpur, Malaysia

**P 42.** Prevalence of depression in cancer patients: cultural influence

**C.G. Ng, S. Thanasan, N.Z. Zainal**

University Malaya, Kuala Lumpur, Malaysia

**P 43.** Altered quality of life in epilepsy: significance of interictal depression

**K. Todorova-Nenova**

MHAT St.Marina, I Psychiatric Clinic, Varna, Bulgaria

**P 44.** Influence of depression, sociodemographic and seizure-related variables on quality of life of adults with epilepsy

**K. Todorova-Nenova**

MHAT St.Marina, I Psychiatric Clinic, Varna, Bulgaria

**P 45.** Improving compliance and treatment outcome in bipolar and schizophrenic patients by using short message text service (SMS).

**E. Van Gent<sup>1</sup>, E. Knoppert Van Der Klein<sup>2</sup>**

<sup>1</sup>Faneurop, department psychiatry, Arnhem, The Netherlands, <sup>2</sup>Rivierduinen, GGZ Rijnstreek, Alphen a/d Rijn, The Netherlands

**P 46.** Psychiatrists' awareness of adherence to antipsychotic medication in bipolar disorder: results from a survey conducted across eight European countries

**E. Vieta<sup>1</sup>, J-M Azorin<sup>2</sup>, M. Bauer<sup>3</sup>, S. Frangou<sup>4</sup>, G. Perugi<sup>5</sup>, G. Martinez<sup>6</sup>, A. Schreiner<sup>7</sup>**

<sup>1</sup>Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain, <sup>2</sup>Sainte Marguerite Hospital, SHU Psychiatrie Adultes, University of Marseilles, Marseille, France, <sup>3</sup>Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, <sup>4</sup>Section of Neurobiology of Psychosis, Institute of Psychiatry, King's College London, London, UK, <sup>5</sup>Department of Psychiatry, University of Pisa, Pisa, Italy, <sup>6</sup>Janssen-Cilag EMEA Medical Affairs, Madrid, Spain, <sup>7</sup>Janssen-Cilag EMEA Medical Affairs, Neuss, Germany



### Audio-Visual Facilities

Speakers must go to the preview room in order to validate and download their presentation files, at least forty minutes before the beginning of the sessions. Please respect this schedule, otherwise, the performance of the received presentations is not guaranteed.

We cannot accept presentations delivered in room directly (without previewing). Coffee breaks and midday are the busiest time in the preview room. So we recommend you to come to the preview early in the morning or during other presentations. An hostess will guide and assist the speakers for checking and downloading their presentation files.

### European Accreditation

15 UEMS credits have been granted to this Congress. UEMS credits are recognized by the American Medical Association for conversion to AMA PRA Category 1 Credit.

### Certificate of Attendance

A certificate of attendance is provided, on request, at the registration desk on the last day of the Forum.

## GENERAL INFORMATION



**The “10th International Forum on Mood and Anxiety Disorders”** is held at the Hilton Hotel Vienna, Am Stadtpark 1, 1030 Vienna, Austria from 17-19 November 2010.

### Admission (Badges)

The participant's name badge is provided at the registration desk. All participants are requested to wear the badge throughout the Forum. Only badge holders are admitted to the appropriate sessions, exhibition and social events.

### Coffee breaks and Lunches

During the Forum sessions, coffee breaks and lunches are served free of charge to all registered participants, wearing the badge.

### Electricity

The standard voltage in Austria is 220 V. The Austrian network supply a frequency of 50Hz. Plugs are continental-style two-pins.

### Currency

The official currency in Austria is the Euro.

### Insurance

The Forum organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Forum participants and accompanying persons, either during



## GENERAL INFORMATION

or as a result of the Forum. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice upon Registration to the Forum and booking of your travel.

### Language

The official language of the Forum is English. No simultaneous translation is provided.

### Mobile phones

Delegates are kindly requested to switch their mobile phones off during the scientific sessions.

### Secretariat Desk

The Secretariat desk is and stay open on Wednesday, 17<sup>th</sup> November 2010 and stay open all through the Forum as follow:

• Wednesday, November 17	12h00 - 18h00
• Thursday, November 18	08h15 - 18h00
• Friday, November 19	08h15 - 16h15

### Smoking Policy

The 10<sup>th</sup> International Forum on Mood and Anxiety Disorders is a non-smoking venue. Forum participants are kindly requested to refrain from smoking in the Forum venue, including the exhibition area and restrooms.

### Tips

Service is usually included in the prices in bars and restaurants, but tips are welcome.

### Useful Telephone Numbers

• Ambulance and Emergency Services	144
• Emergency Doctor	141
• Euro Emergency number	112
• Police	133
• Fire department	122
• Night and weekend dental services	5 12 20 78
• Pharmacies open nights and Sunday	1550

### Other Useful Numbers

- Vienna International Airport: infoline **+43 7007 22233** (24 hours) [www.viennairport.com](http://www.viennairport.com)
- Taxi: **+43 699 19780413**



# **The 11<sup>th</sup> International Forum on Mood and Anxiety Disorders**

will be held in Budapest, Hungary  
from 9 -11 November, 2011

**Save the date  
9 - 11 NOVEMBER  
2011**





# Cipralex - the power to tackle depression at its core

## Leaving no one behind

**Presentation:** "Cipralex". Tablets containing 5, 10, 15 or 20 mg escitalopram (as oxalate). **Indications:** Major depression. Generalised anxiety disorder. Panic disorder. Social anxiety disorder. Obsessive compulsive disorder. **Dosage:** Usual dose is 10 mg daily. Maximum dose 20 mg daily. In elderly (>65 years), in panic disorder patients and in patients with reduced hepatic function an initial dose of 5 mg daily is recommended. Caution in patients with severely reduced renal function. Not recommended in children

and adolescents (<18 years). When stopping treatment the dose should be gradually reduced over a period of one or two weeks. **Contraindications:** Hypersensitivity to escitalopram. Concomitant treatment with MAOIs. **Pregnancy and lactation:** Careful consideration prior to use in pregnant women. Breast-feeding women should not be treated. **Precautions:** The special warnings and precautions which apply to the class of SSRIs. **Drug interactions:** MAOIs, serotonergic drugs, drugs lowering the seizure threshold, lithium

tryptophan, St. John's Wort, anticoagulants, drugs metabolised mainly by enzymes CYP 2D6 or 2C19. **Adverse events:** Most frequent during the first or second week, very common is nausea, less frequent is adverse events comprising to the SSRI class. **Overdosage:** Doses between 400 mg and 800 mg of escitalopram alone have been taken without any severe symptoms. Consult full prescribing information before prescribing. H. Lundbeck A/S, Copenhagen, Denmark. Date of preparation: February 2010

Lundbeck



**Cipralex**  
escitalopram